Overview
Altered behavior in Alzheimer's disease refers to significant changes in patient conduct, often manifesting as agitation, aggression, apathy, or other neuropsychiatric symptoms, impacting daily functioning and caregiver burden 1.Diagnosis
Assess cognitive function using standardized scales like the Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA) 1.
Evaluate behavioral changes through structured psychiatric assessments such as the Neuropsychiatric Inventory (NPI) 1.
Monitor for fluctuations in consciousness levels using the Glasgow Coma Scale (GCS), though interrater reliability can be variable 2.Management
First-line treatments: Non-pharmacological interventions including environmental modifications, structured routines, and cognitive stimulation therapy 1.
Pharmacological interventions:
- Antipsychotics (e.g., risperidone, olanzapine) for severe agitation; use cautiously due to increased risk of adverse effects like stroke 1.
- Anxiolytics (e.g., lorazepam) for acute anxiety, though long-term use is discouraged 1.
Adjunctive treatments: Consider cholinesterase inhibitors (e.g., donepezil) to potentially improve cognitive symptoms and indirectly affect behavior 1.Special Populations
Elderly: Increased sensitivity to side effects of pharmacological treatments; prioritize non-pharmacological approaches 1.
Comorbidities: Tailor treatment plans considering coexisting conditions like cardiovascular disease, which may limit antipsychotic use 1.Key Recommendations
Utilize structured assessments like the Neuropsychiatric Inventory (NPI) to evaluate behavioral changes in Alzheimer's disease (Evidence: Moderate 1).
Prioritize non-pharmacological interventions for managing altered behavior due to their efficacy and safety profile (Evidence: Moderate 1).
Exercise caution with antipsychotic use in elderly patients due to potential increased risk of adverse events (Evidence: Moderate 1).
Ensure interrater reliability in assessing consciousness levels using validated scales like the GCS, despite noted variability (Evidence: Weak 2).References
1 Staquet C, Vanhaudenhuyse A, Kandeepan S, Sanders RD, Ribeiro de Paula D, Brichant JF et al.. Changes in Intrinsic Connectivity Networks Topology Across Levels of Dexmedetomidine-Induced Alteration of Consciousness. Anesthesia and analgesia 2024. link
2 Gill MR, Reiley DG, Green SM. Interrater reliability of Glasgow Coma Scale scores in the emergency department. Annals of emergency medicine 2004. link00814-x)